N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine
AssigneeGlucox Biotech AB
InventorsPer Wikström, Erik Walum, Mona Wilcke
Life of this patent
Estimating the term…
Abstract
The compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamineor a pharmaceutically acceptable salt of said compound. The compound is useful the treatment of a condition or disorder associated with nicotinamide adenine dinucleotide phosphate oxidaseactivity. A pharmaceutical composition comprising the compound.
Claims13
The compound
- N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine, or a pharmaceutically acceptable salt of said compound.
-4. (canceled)
-16. (canceled)
A method of treatment of a condition or disorder selected from endocrine disorders, cardiovascular disorders, respiratory disorders, metabolism disorders, skin disorders, bone disorders, neuroinflammatory and/or neurodegenerative disorders, kidney diseases, reproduction disorders, diseases affecting the eye and/or the lens and/or conditions affecting the inner ear, inflammatory disorders, liver diseases, pain, cancers, allergic disorders, traumatisms, septic, hemorrhagic and anaphylactic shock, diseases or disorders of the gastrointestinal system, abnormal angiogenesis and angiogenesis-dependent conditions, lung infections, acute lung injury, pulmonary arterial hypertension, obstructive lung disorders, and fibrotic lung disease, by administering the compound N2-(3,4-dimethylphenyl)-6-((4-(p-tolyl)piperazin-1-yl)methyl)-1,3,5-triazine-2,4-diamine, or a pharmaceutically acceptable salt of said compound, to a mammal in need of such treatment.
Dependencies are inferred from the claim text.